| Title: | Outcome of maintenance systemic chemotherapy with drug-free interval for metastatic urothelial carcinoma |
| Authors: | Abe, T. Browse this author →KAKEN DB |
| Minami, K. Browse this author |
| Harabayashi, T. Browse this author |
| Sazawa, A. Browse this author |
| Chiba, H. Browse this author |
| Kikuchi, H. Browse this author |
| Miyata, H. Browse this author |
| Matsumoto, R. Browse this author |
| Osawa, T. Browse this author |
| Maruyama, S. Browse this author |
| IshizakiIshizaki, J. Browse this author |
| Mochizuki, T. Browse this author |
| Chiba, S. Browse this author |
| Akino, T. Browse this author |
| Murakumo, M. Browse this author |
| Miyajima, N. Browse this author |
| Tsuchiya, K. Browse this author |
| Murai, S. Browse this author |
| Shinohara, N. Browse this author →KAKEN DB |
| Keywords: | metastatic urothelial carcinoma |
| systemic chemotherapy |
| maintenance chemotherapy |
| Issue Date: | Oct-2019 |
| Publisher: | Oxford University Press |
| Journal Title: | Japanese journal of clinical oncology |
| Volume: | 49 |
| Issue: | 10 |
| Start Page: | 965 |
| End Page: | 971 |
| Publisher DOI: | 10.1093/jjco/hyz084 |
| Abstract: | Objective: Aiming to achieve long-term disease control, maintenance systemic chemotherapy (MSC) with a 1-3-month drug-free interval is continued in selected patients. We report our experience of MSC for metastatic urothelial carcinoma (UC). Methods: Of 228 metastatic UC patients treated with systemic chemotherapy, 40 (17.5%, 40/228) had continuously undergone MSC. Data on the regimen, cycle number, and reason for the discontinuation of MSC were also collected. We analyzed OS from the initiation of MSC until death or the last follow-up, using the log-rank test to assess the significance of differences. Results: The median number of cycles of chemotherapy was 6, and the responses were CR in 6, PR in 20, SD in 13, and PD in 1 before MSC. Gemcitabine plus CDDP or carboplatin was mainly performed as MSC (70%, 28/40). MSC was repeated quarterly in 30 (75%, 30/40), every two months in 8 (20%, 8/40), and with other intervals in 2 (5%, 2/40). Overall, a median of 3.5 cycles (range: 1-29) of MSC was performed. The reason for the discontinuation of MSC was PD in 24 (60%, 24/40), favorable disease control in 9 (22.5%, 9/40), and myelosuppression in 3 (7.5%, 3/40), and for other reasons in 2 (5%, 2/40). MSC was ongoing in 2 (5%, 2/40). The median OS was 27 months from the initiation of MSC. PS0 (P = 0.0169), the absence of lung metastasis (P = 0.0387), and resection of the primary site (P = 0.0495) were associated with long-term survival after MSC. Conclusions: In selected patients, long-term systemic chemotherapy could be performed with a drug-free interval. Our maintenance strategy with cytotoxic drugs may become one of the treatment options for long-term disease control. |
| Rights: | http://creativecommons.org/licenses/by-nc/ 4.0/ |
| Type: | article |
| URI: | http://hdl.handle.net/2115/76801 |
| Appears in Collections: | 医学院・医学研究院 (Graduate School of Medicine / Faculty of Medicine) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)
|
